BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

BeiGene, Ltd. American Depositary Shares

Sold all BGNE

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Greg Kajewski

Mark W

Mahidhar Duvvuru

New position in BGNE

Andrew Cameron

Sold 50% of BGNE

Bought to close all BGNE

Carlos aguilar

Sold 62% of BGNE

Bought 30% more BGNE

Bought 25% more BGNE

Bought 14% more BGNE

Bought 17% more BGNE

Bought 20% more BGNE

Bought 67% more BGNE

Bought 200% more BGNE